![]() ![]() Sanofi Genzyme developed Isatuximab (SAR 650984) which is another anti-CD38 antibody that has shown single-agent activity in Phase I testing among heavily pre-treated myeloma patients. In this video transplant recipients talk about the impact of transplant on their work and finances, how they coped and what helped them. Conventionally, improved PFS after ASCT is attributed to cytoreduction from myeloablative chemotherapy. Follow Sanofi Genzyme on Twitter #myeloma awareness initiative continues to BUILD a bridge for raising funds! Clinical studies show that autologous stem cell transplantation (ASCT) remains efficacious in eligible patients, providing a progression free survival (PFS) benefit beyond novel therapies alone. Leukemia patients usually receive an allogeneic stem cell transplant. This type of transplant is used most frequently to treat multiple myeloma and lymphoma. So please start Tweeting and be sure to include the hashtags #IMambo4Myeloma and #BMTTandem16 in each of your tweets and RTs. Autologous stem cell transplants are an option for patients whose cancer is in remission or has stabilized. Sanofi Genzyme will make a $10.00 donation to CIBMTR and ASBMT for every 10 Tweets and Retweets which include the Hashtags #IMambo4Myeloma and #BMTTandem16, starting NOW through February 23rd. To help raise #MultipleMyeloma awareness among bone and marrow transplant specialist members of the Center for International Bone & Marrow Transplant Research (CIBMTR) and the American Society of Blood & Marrow Transplant (ASBMT), Sanofi Genzyme will raise recognition for the Multiple Myeloma Community at the upcoming #BMTTandem16 Annual Meeting in Ho nolulu, Hawaii, February 18th through February 22nd. Overview of autologous stem cell transplantation There has been a dramatic increase in the number of autologous peripheral blood stem cell transplants over the last decade. Faster recovery of cell counts, lesser transplant morbidity, shorter hospital stay and reduced cost compared with marrow autografts have been the main advantages of autologous peripheral blood cell over marrow transplants. #IMamboforMyeloma is going to #BMTTandem16 ! There has been a dramatic increase in the number of autologous peripheral blood stem cell transplants over the last decade. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |